Last reviewed · How we verify
DIATRIZOATE SODIUM
At a glance
| Generic name | DIATRIZOATE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Urticaria with erythema
- Hypoxia
- Acute dyspnea
- Tachyarrhythmia
- Anaphylaxis
Key clinical trials
- Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
- Optimizing Treatment of Adhesive Small Bowel Obstruction (PHASE3)
- Fluorescence Cholangiography During Cholecystectomy - a RCT (NA)
- Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure (PHASE3)
- Gastrografin for Treating Small Bowel Obstruction in Children (PHASE2, PHASE3)
- The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients. (PHASE4)
- Serum Thyroid Function After Iodinated Contrast Administration
- Uniformity of Oral Contrast Material in the Bowel
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DIATRIZOATE SODIUM CI brief — competitive landscape report
- DIATRIZOATE SODIUM updates RSS · CI watch RSS